AR073226A1 - Forma polimorfica cristalina b de la n-(2-aminofenil)-4-[n-(piridin-3-il)metoxicarbonilamino-metil] benzamida - Google Patents

Forma polimorfica cristalina b de la n-(2-aminofenil)-4-[n-(piridin-3-il)metoxicarbonilamino-metil] benzamida

Info

Publication number
AR073226A1
AR073226A1 ARP090103317A AR073226A1 AR 073226 A1 AR073226 A1 AR 073226A1 AR P090103317 A ARP090103317 A AR P090103317A AR 073226 A1 AR073226 A1 AR 073226A1
Authority
AR
Argentina
Prior art keywords
aminophenyl
methyl
crystalline
metoxicarbonylamine
benzamida
Prior art date
Application number
Other languages
English (en)
Spanish (es)
Inventor
Gabriele Winter
Jens Geisler
Matthias Schneider
Michael Gottfried
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41133825&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR073226(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of AR073226A1 publication Critical patent/AR073226A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP090103317 2008-08-29 2009-08-28 Forma polimorfica cristalina b de la n-(2-aminofenil)-4-[n-(piridin-3-il)metoxicarbonilamino-metil] benzamida AR073226A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9304608P 2008-08-29 2008-08-29
EP08163274 2008-08-29

Publications (1)

Publication Number Publication Date
AR073226A1 true AR073226A1 (es) 2010-10-20

Family

ID=41133825

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090103317 AR073226A1 (es) 2008-08-29 2009-08-28 Forma polimorfica cristalina b de la n-(2-aminofenil)-4-[n-(piridin-3-il)metoxicarbonilamino-metil] benzamida

Country Status (35)

Country Link
US (2) US7973166B2 (enExample)
EP (1) EP2350005B1 (enExample)
JP (1) JP4921616B2 (enExample)
KR (1) KR101073760B1 (enExample)
CN (1) CN102137846B (enExample)
AR (1) AR073226A1 (enExample)
AT (1) ATE538094T1 (enExample)
AU (1) AU2009286982C1 (enExample)
BR (1) BRPI0918580B8 (enExample)
CA (1) CA2735294C (enExample)
CO (1) CO6351736A2 (enExample)
CR (2) CR20110107A (enExample)
CY (1) CY1112645T1 (enExample)
DK (1) DK2350005T3 (enExample)
DO (1) DOP2011000064A (enExample)
EA (1) EA016811B1 (enExample)
EC (1) ECSP11010849A (enExample)
ES (1) ES2378640T3 (enExample)
HN (1) HN2011000609A (enExample)
HR (1) HRP20120183T8 (enExample)
IL (1) IL211276A (enExample)
MA (1) MA32610B1 (enExample)
MX (1) MX2011002248A (enExample)
MY (1) MY149058A (enExample)
NZ (1) NZ591387A (enExample)
PE (2) PE20141062A1 (enExample)
PL (1) PL2350005T3 (enExample)
PT (1) PT2350005E (enExample)
RS (1) RS52164B (enExample)
SI (1) SI2350005T1 (enExample)
SM (1) SMT201200026B (enExample)
SV (1) SV2011003846A (enExample)
TW (1) TWI427062B (enExample)
WO (1) WO2010022988A1 (enExample)
ZA (1) ZA201102285B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA016811B1 (ru) 2008-08-29 2012-07-30 Байер Фарма Акциенгезельшафт Полиморф в n-(2-аминофенил)-4-[n-(пиридин-3-ил)метоксикарбо-ниламинометил]бензамида (ms-275), способ его получения и применение для получения лекарственного средства для лечения заболеваний
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
FR2977492B1 (fr) * 2011-07-04 2013-07-05 Servier Lab Nouvelle association entre le n-hydroxy-4-{2-[3-(n,n-dimethylaminomethyl) benzofuran-2-ylcarbonylamino]ethoxy}benzamide et le folfox
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
JP2017537084A (ja) 2014-11-12 2017-12-14 トラコン ファーマシューティカルズ、インコーポレイテッド 抗エンドグリン抗体及びその用途
EP3168210A1 (en) 2015-11-13 2017-05-17 Sandoz Ag Crystalline forms of entinostat
WO2017216761A1 (en) * 2016-06-17 2017-12-21 Dr. Reddy's Laboratories Limited Solid forms of entinostat
CN110944978A (zh) * 2017-07-28 2020-03-31 杭州领业医药科技有限公司 含恩替诺特的化合物,其化合物晶型及其制备方法和药物组合物
JP2024517919A (ja) 2021-05-10 2024-04-23 マクファーラン スミス リミテッド エンチノスタットの新規形態

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3354090B2 (ja) * 1996-09-30 2002-12-09 シエーリング アクチエンゲゼルシャフト 分化誘導剤
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
JP4030683B2 (ja) * 1998-07-24 2008-01-09 三井化学株式会社 ベンズアミド誘導体の合成法
US6320078B1 (en) * 1998-07-24 2001-11-20 Mitsui Chemicals, Inc. Method of producing benzamide derivatives
JP2001064177A (ja) * 1999-08-16 2001-03-13 Schering Ag ベンズアミド誘導体を有効成分とする製剤
JP4360660B2 (ja) * 1999-11-09 2009-11-11 三井化学株式会社 モノアシルフェニレンジアミン誘導体の精製法
PE20050206A1 (es) * 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
EA016811B1 (ru) 2008-08-29 2012-07-30 Байер Фарма Акциенгезельшафт Полиморф в n-(2-аминофенил)-4-[n-(пиридин-3-ил)метоксикарбо-ниламинометил]бензамида (ms-275), способ его получения и применение для получения лекарственного средства для лечения заболеваний

Also Published As

Publication number Publication date
AU2009286982B2 (en) 2011-06-23
BRPI0918580B8 (pt) 2021-05-25
PT2350005E (pt) 2012-03-12
SI2350005T1 (sl) 2012-03-30
EA201100354A1 (ru) 2011-10-31
ES2378640T3 (es) 2012-04-16
RS52164B (sr) 2012-08-31
CN102137846A (zh) 2011-07-27
MX2011002248A (es) 2011-03-29
DK2350005T3 (da) 2012-03-19
HN2011000609A (es) 2014-09-29
JP4921616B2 (ja) 2012-04-25
CA2735294C (en) 2013-10-15
CR20110107A (es) 2011-04-28
CR20160465A (es) 2016-12-06
US7973166B2 (en) 2011-07-05
PE20141062A1 (es) 2014-09-19
EA016811B1 (ru) 2012-07-30
AU2009286982A1 (en) 2010-03-04
ZA201102285B (en) 2011-12-28
CN102137846B (zh) 2014-04-23
AU2009286982C1 (en) 2012-04-26
KR20110038187A (ko) 2011-04-13
HRP20120183T8 (en) 2012-11-30
IL211276A0 (en) 2011-04-28
DOP2011000064A (es) 2011-03-31
NZ591387A (en) 2012-03-30
TW201014820A (en) 2010-04-16
HRP20120183T1 (hr) 2012-03-31
TWI427062B (zh) 2014-02-21
US20100056585A1 (en) 2010-03-04
SV2011003846A (es) 2011-07-27
MA32610B1 (fr) 2011-09-01
CA2735294A1 (en) 2010-03-04
KR101073760B1 (ko) 2011-10-13
IL211276A (en) 2014-07-31
MY149058A (en) 2013-07-15
PE20110677A1 (es) 2011-09-16
BRPI0918580B1 (pt) 2020-11-24
BRPI0918580A2 (pt) 2015-12-01
ATE538094T1 (de) 2012-01-15
ECSP11010849A (es) 2011-03-31
WO2010022988A1 (en) 2010-03-04
BRPI0918580A8 (pt) 2017-07-11
HK1160107A1 (en) 2012-08-10
PL2350005T3 (pl) 2012-05-31
JP2012500819A (ja) 2012-01-12
EP2350005A1 (en) 2011-08-03
EP2350005B1 (en) 2011-12-21
SMT201200026B (it) 2012-07-10
CO6351736A2 (es) 2011-12-20
USRE45499E1 (en) 2015-04-28
CY1112645T1 (el) 2016-02-10

Similar Documents

Publication Publication Date Title
AR073226A1 (es) Forma polimorfica cristalina b de la n-(2-aminofenil)-4-[n-(piridin-3-il)metoxicarbonilamino-metil] benzamida
EA201170154A1 (ru) Производные пиридинопиридинонов, способ их получения и применение в терапии
MX2012000973A (es) Compuestos para la reduccion de produccion de beta- amiloide.
EA201170617A1 (ru) Пиразолиламинопиридины в качестве ингибиторов fak
NZ620000A (en) Prodrug forms of kinase inhibitors and their use in cancer therapy
MX2019015200A (es) Compuestos de diarilhidantoina.
EA201100880A1 (ru) Бензонафтиридиновые соединения в качестве ингибиторов аутотаксина
MX2008002293A (es) Uso novedoso de compuestos peptidicos para tratar dolor muscular.
CL2011001830A1 (es) Forma cristalina del hidrocloruro de n-[(1s)-2-amino-1-[(3-fluorofenil)metil]etil]-5-cloro-4-(4-cloro-1-metil-1h-pirazol-5-il)-2-tiofenocarboxamida; composicion farmaceutica; combinacion farmaceutica; proceso para preparar la composicion farmaceutica; y su uso para tratar o disminuir una enfermedad seleccionada de cancer y artritis.
UA102289C2 (ru) Гербициды, полученные из циклопентадиона
EA201170344A1 (ru) Азаиндольные ингибиторы iap
MY146084A (en) Benzyl amines, a process for their production and their use as anti-inflammatory agents
MX339300B (es) Inhibidores de molecula pequeña de la activacion n-terminal del receptor de androgenos.
CY1115729T1 (el) Τρικυκλικη ενωση και φαρμακευτικη χρηση αυτης
GB0508318D0 (en) Organic compounds
IL176111A0 (en) 2-(1h-indolylsulfanyl)-benzyl amine derivatives as ssri
DE602006009789D1 (de) Acetylenderivate
CY1107562T1 (el) Χρηση των ν-(2-αρυλ-προπιονυλ)-σουκλφοναμιδιων για τη θepαπεια του τραυματος του νωτιαιου μυελου
TW200633977A (en) Novel process for the manufacture of 3-pyrrolidin-2-yl-propionic acid derivatives
TW200716564A (en) Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
UA85701C2 (ru) Способ получения ингибиторов триптазы
EA200701852A1 (ru) Производные аминокислот
TNSN08268A1 (en) Crystalline form of vinflunine ditartrate
NZ590076A (en) Treating plexiform neurofibroma and related tumors
MX2011007641A (es) Nuevos compuestos heterociclicos como inhibidores de metap-2.

Legal Events

Date Code Title Description
FB Suspension of granting procedure